This document is an excerpt from the EUR-Lex website
Document 62015CA0629
Joined Cases C-629/15 P and C-630/15 P: Judgment of the Court (Eighth Chamber) of 28 June 2017 — Novartis Europharm Ltd v European Commission, Teva Pharma BV (C-629/15 P), Hospira UK Ltd (C-630/15 P) (Appeal — Medicinal products for human use — Marketing authorisation — Regulation (EEC) No 2309/93 — Centralised procedure at European Union level — Development of a medicinal product that was the subject of a marketing authorisation for other therapeutic indications — Separate marketing authorisation and new trade name — Directive 2001/83/EC — Second subparagraph of Article 6(1) and Article 10(1) — Concept of a ‘global marketing authorisation’ — Regulatory data protection period)
Joined Cases C-629/15 P and C-630/15 P: Judgment of the Court (Eighth Chamber) of 28 June 2017 — Novartis Europharm Ltd v European Commission, Teva Pharma BV (C-629/15 P), Hospira UK Ltd (C-630/15 P) (Appeal — Medicinal products for human use — Marketing authorisation — Regulation (EEC) No 2309/93 — Centralised procedure at European Union level — Development of a medicinal product that was the subject of a marketing authorisation for other therapeutic indications — Separate marketing authorisation and new trade name — Directive 2001/83/EC — Second subparagraph of Article 6(1) and Article 10(1) — Concept of a ‘global marketing authorisation’ — Regulatory data protection period)
Joined Cases C-629/15 P and C-630/15 P: Judgment of the Court (Eighth Chamber) of 28 June 2017 — Novartis Europharm Ltd v European Commission, Teva Pharma BV (C-629/15 P), Hospira UK Ltd (C-630/15 P) (Appeal — Medicinal products for human use — Marketing authorisation — Regulation (EEC) No 2309/93 — Centralised procedure at European Union level — Development of a medicinal product that was the subject of a marketing authorisation for other therapeutic indications — Separate marketing authorisation and new trade name — Directive 2001/83/EC — Second subparagraph of Article 6(1) and Article 10(1) — Concept of a ‘global marketing authorisation’ — Regulatory data protection period)
OJ C 283, 28.8.2017, p. 4–5
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
28.8.2017 |
EN |
Official Journal of the European Union |
C 283/4 |
Judgment of the Court (Eighth Chamber) of 28 June 2017 — Novartis Europharm Ltd v European Commission, Teva Pharma BV (C-629/15 P), Hospira UK Ltd (C-630/15 P)
(Joined Cases C-629/15 P and C-630/15 P) (1)
((Appeal - Medicinal products for human use - Marketing authorisation - Regulation (EEC) No 2309/93 - Centralised procedure at European Union level - Development of a medicinal product that was the subject of a marketing authorisation for other therapeutic indications - Separate marketing authorisation and new trade name - Directive 2001/83/EC - Second subparagraph of Article 6(1) and Article 10(1) - Concept of a ‘global marketing authorisation’ - Regulatory data protection period))
(2017/C 283/05)
Language of the case: English
Parties
Appellant: Novartis Europharm Ltd (represented by: C. Schoonderbeek, advocaat)
Other parties to the proceedings: European Commission (represented by: K. Mifsud-Bonnici, A. Sipos and M. Šimerdová, acting as Agents), Teva Pharma BV (represented by: K. Bacon QC, instructed by C. Firth, Solicitor) (C-629/15 P), Hospira UK Ltd (represented by: J. Stratford QC, instructed by E. Vickers and N. Stoate, Solicitors) (C-630/15 P)
Operative part of the judgment
The Court:
|
1. |
Dismisses the appeals in Cases C-629/15 P and C-630/15 P; |
|
2. |
Orders Novartis Europharm Ltd to bear its own costs and to pay those incurred by the European Commission, by Teva Pharma BV and by Hospira UK Ltd in Cases C-629/15 P and C-630/15 P. |